Atorvastatin Improves Hepatic Lipid Metabolism and Protects Renal Damage in Adenine-Induced Chronic Kidney Disease in Sprague-Dawley Rats.

Conclusions: Atorvastatin improved hepatic tissue lipid metabolism and renal function in adenine-induced CKD rats. PMID: 31828139 [PubMed - in process]
Source: Biomed Res - Category: Research Authors: Tags: Biomed Res Int Source Type: research

Related Links:

CONCLUSION: Hospitalization or death was not influenced by the type of RO, Al accumulation, or TMV classification. An elevated prevalence of osteoporosis and Al accumulation was detected. PMID: 31967202 [PubMed - as supplied by publisher]
Source: Jornal Brasileiro de Nefrologia - Category: Urology & Nephrology Tags: J Bras Nefrol Source Type: research
Conclusion: LT for children with PA is a viable treatment option with acceptable outcomes.
Source: Journal of Pediatric Gastroenterology and Nutrition - Category: Gastroenterology Tags: Original Articles: Hepatology Source Type: research
In conclusion, data revealed no correlation between ex vivo and in vivo studies explained by the collapse of the follicles in ex vivo skin permeation study, leaving only the lipoidal pathway for NE to pass through, thus only NE components, neither nanosizing nor other reported mechanisms, are the main influencing factors. In vivo experiments suggested that o/w NE changed ATOR pathway to follicular delivery leading to accumulation of NE in follicles and consequently a prolonged plasma profile.Graphical abstract
Source: International Journal of Pharmaceutics - Category: Drugs & Pharmacology Source Type: research
Conclusions: Hyperuricemia and hypertension may have a synergistic interaction towards renal function loss in addition to their independent impacts. Our findings may provide a straightforward illustration which is easy for the public to realize the hazard of coexistent hypertension and hyperuricemia on renal injury. PMID: 31962051 [PubMed - as supplied by publisher]
Source: Postgraduate Medicine - Category: Internal Medicine Tags: Postgrad Med Source Type: research
Condition:   Chronic Kidney Diseases Intervention:   Diagnostic Test: Multiparametric renal MRI Sponsors:   University Hospitals of Derby and Burton NHS Foundation Trust;   University of Nottingham;   Queen Elizabeth University Hospital Glasgow;   Royal Infirmary of Edinburgh;   University of Edinburgh;   Newcastle University;   Newcastle-upon-Tyne Hospitals NHS Trust;   Universi ty of Leeds;   The Leeds Teaching Hospitals NHS Trus...
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
AbstractCardiovascular disease is the leading cause of death in patients with chronic kidney disease (CKD) and CKD is considered a coronary artery disease risk equivalent. So far, statins have been the mainstay of primary and secondary prevention of cardiovascular disease in the general population. However, their benefit on outcomes is limited and controversial in CKD patients and new therapeutic approaches to reduce cardiovascular risk are needed. Monoclonal antibodies targeting proprotein convertase subtilisin/kexin 9 (PCSK9) reduce low-density lipoprotein cholesterol (LDL-C) and lipoprotein(a) in high-risk populations a...
Source: Drugs - Category: Drugs & Pharmacology Source Type: research
Conclusion: Anti-PLA2R IHC is a specific marker to distinguish primary MN from secondary MN. 
Nephron Extra 2017;7:1 –9
Source: Nephron Extra - Category: Urology & Nephrology Source Type: research
Authors: Mikolasevic I, Žutelija M, Mavrinac V, Orlic L Abstract Patients with chronic kidney disease (CKD), including those with end-stage renal disease, treated with dialysis, or renal transplant recipients have an increased risk for cardiovascular disease (CVD) morbidity and mortality. Dyslipidemia, often present in this patient population, is an important risk factor for CVD development. Specific quantitative and qualitative changes are seen at different stages of renal impairment and are associated with the degree of glomerular filtration rate declining. Patients with non-dialysis-dependent CKD have low high-...
Source: International Journal of Nephrology and Renovascular Disease - Category: Urology & Nephrology Tags: Int J Nephrol Renovasc Dis Source Type: research
Conclusion: Anti-PLA2R IHC is a specific marker to distinguish primary MN from secondary MN. 
Nephron Extra 2017;7:1 –9
Source: Nephron Extra - Category: Urology & Nephrology Source Type: research
In this study, the effectiveness of lipid-lowering therapy on mortality and cardiovascular outcomes is explored.Summary: Mortality is inversely associated with the cholesterol level. The degree of inflammation and wasting is a stronger predictor of mortality than are cholesterol levels. Treatment with statins reduces the risk of death and cardiovascular outcomes among patients not yet requiring renal replacement therapy, but is not effective once dialysis is initiated, most likely because other processes, such as inflammation, not affected by lipid-lowering therapy, dominate in the causal pathway leading to adverse outcome...
Source: Blood Purification - Category: Hematology Source Type: research
More News: Atorvastatin Calcium | Cardiology | Cardiovascular | Cholesterol | Chronic Kidney Disease | Heart | Lecithin | Lipitor | Nephrotic Syndrome | Research | Statin Therapy | Study | Urology & Nephrology | Zivast